NYSE:BHVNBiotechs
A Look at Biohaven’s Valuation Following $175 Million Share Offering and Recent FDA Setback
Biohaven (NYSE:BHVN) just completed a $175 million follow-on public offering, issuing new shares at $7.50, which is lower than its prior trading price. This move is aimed at bolstering the company’s balance sheet after recent challenges.
See our latest analysis for Biohaven.
Biohaven’s recent stock performance has been dominated by sharp moves, most notably a roughly 48% drop in the last three months after the FDA declined to approve its experimental drug. This led to a follow-on stock...